Abstract
Next generation sequencing (NGS) has been applied in scientific research and clinical practice of mature lymphoid malignancies. The applications of NGS in the study of pathogenesis, treatment and prognosis evaluation, mechanisms of resistance to treatment in lymphoid malignancies have been reported in the 57th American Society of Hematology (ASH) annual meeting. This article summarized the advances in the use of NGS in mature lymphoid malignancies by reviewing several representative reports. Key words: Mature lymphoid malignancies; Next generation sequencing; American Society of Hematology annual meeting
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
